Exosome-based detection of EGFR T790M in plasma and pleural fluid of prospectively enrolled non-small cell lung cancer patients after first-line tyrosine kinase inhibitor therapy

Table 3 Performance comparison for detection of the EGFR T790M mutation between the Cobas assay, ddPCR, and NGS using plasma from NSCLC patients

EGFR genotype	TP and TN^a (38 cases with NGS results)	Cobas assay using cfDNA (n = 54)		ddPCR using cfDNA + exoTNA (n = 54)		NGS using cfDNA + exoTNA (n = 38)
EGFR genotype	TP and TN^a (38 cases with NGS results)	Mutant type	Wild-type	Mutant type	Wild-type	Mutant type	Wild-type
Mutant type	17 (15)	11	6	15	2	14	1
Wild-type	37 (23)	0	37	0	37	0	23
Sensitivity,% (95% CI)		64.7 (63.4–66)		88.2 (86.9–89.5)		93.3 (91.7–94.9)
Specificity, % (95% CI)		100 (98.7–101)		100 (98.7–101)		100 (98.4–102)
Accuracy, % (95% CI)		88.9 (87.6–90.2)		96.3 (95–97.6)		97.4 (95.8–99)

^a‘True positive’ was defined as a positive T790M mutation in one or more liquid biopsy platforms among Cobas, ddPCR, and NGS; ‘True negative’ was defined as T790M mutation negative in all tested liquid biopsy platforms
NSCLC non-small cell lung cancer, TP true positive, TN true negative, CI confidence interval

ISSN: 1475-2867